ATP7A and cancer: Thus, considering the crucial roles of Mnk-eIF4E and mTORC1 signaling in cancer growth and progression, and the challenges posed by the TNBC, we believe that VNLG-152R may be an ideal novel small molecule therapeutics for the treatment of patients with primary/metastatic TNBC and potentially other breast cancer subtypes, including other malignancies with dysregulated Mnk-eIF4E/mTORC1 signaling.